63
1 Lisa Villarroel, MD MPH Medical Director, Division of Public Health Preparedness Arizona Department of Health Services Disclosures: None

Syphilis Roadshow 03.17.18 PC VERSION · symptom recognition secondary tertiary early latent late latent joe engelman, sf city clinic. 21 symptom recognition primary secondary tertiary

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

  • 1

    Lisa Villarroel, MD MPHMedical Director, Division of Public Health Preparedness

    Arizona Department of Health Services

    Disclosures:

    None

  • 2

    Fitzgerald TJ, Cleveland P, Johnson RC et al: Scanning electron microscopy of Treponema pallidum (Nichols strain) attached to cultured mammalian cells. J Bacteriol 130:1333, 1977.

    PRIMARY

    CDC Library

    PRIMARY

  • 3

    CDC PHIL 16750

    PRIMARY

    CDC PHIL 12578 

    PRIMARY SECONDARY

  • 4

    CDC Library 

    PRIMARY SECONDARY

    CDC Picture Cards

    PRIMARY SECONDARY

  • 5

    CDC Library 

    PRIMARY SECONDARY

    PRIMARY SECONDARY EARLYLATENT

  • 6

    PRIMARY SECONDARY EARLYLATENTLATE

    LATENT

    PRIMARY SECONDARY EARLYLATENTLATE

    LATENT

  • 7

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    CDC clinical slides

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 8

    NEUROSYPHILIS CAN OCCUR AT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    TRANSMISSION TO THE FETUS CAN OCCUR AT ….

    NEUROSYPHILIS CAN OCCUR AT

  • 9

    CDC clinical slides

    TRANSMISSION TO THE FETUS CAN OCCUR AT ….

    CDC PHIL 16750

    TRANSMISSION TO THE FETUS CAN OCCUR AT ….

  • 10

    TRANSMISSION TO THE FETUS CAN OCCUR AT ….

    TRANSMISSION TO THE FETUS CAN OCCUR AT ….

    NEUROSYPHILIS CAN OCCUR AT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 11

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 12

    Credit: National Archives.

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 13

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    TRANSMISSION TO THE FETUS CAN OCCUR AT ….

    NEUROSYPHILIS CAN OCCUR AT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 14

    RAT

    E

  • 15

    MEN WHO HAVE SEX WITH MEN

    MEN WHO HAVE SEX WITH WOMEN

    PRIMARY & SECONDARY SYPHILIS CASES

    MEN WHO HAVE SEX WITH MEN

    WOMEN

    MEN WHO HAVE SEX WITH WOMEN

    PRIMARY & SECONDARY SYPHILIS CASES

  • 16

    ARIZONA

    U.S.

    2007 2010 2013 2016

    PRIMARY & SECONDARY SYPHILIS RATE / 100,000

    2012 2013 2014 2015 2016

    PRIMARY & SECONDARY SYPHILIS CASES IN ARIZONA

  • 17

    2012 2013 2014 2015 2016

    BLACK (24)

    AMERICAN INDIAN

    HISPANIC

    WHITE

    ASIAN (4.5)

    PRIMARY & SECONDARY SYPHILIS RATE / 100,000

    0

    10

    20

    2012 2013 2014 2015 20160

    15

    30 ARIZONACASE RATE

    U.S. CASE RATE

    CONGENITAL SYPHILIS CASES & RATES / 100,00

  • 18

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 19

    SYMPTOM RECOGNITION

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    PRIMARY

    SYMPTOM RECOGNITION

    SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 20

    PRIMARY

    SYMPTOM RECOGNITION

    SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    CDC Syphilis Images

    PRIMARY

    SYMPTOM RECOGNITION

    SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    Joe Engelman, SF City Clinic

  • 21

    SYMPTOM RECOGNITION

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    SYMPTOM RECOGNITION

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    CDC Syphilis Images

  • 22

    SYMPTOM RECOGNITION

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    CDC Syphilis Images

    NEUROSYPHILIS CAN OCCUR AT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    Review of Ophthal,, 2008 

  • 23

    NEUROSYPHILIS CAN OCCUR AT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    Review of Ophthal,, 2008 

    SCREEN

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 24

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 25

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    LABORATORY TESTING

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 26

    NONTREPONEMAL TESTS

    RPR, VDRL

    TREPONEMAL TESTS

    TPPA, FTA-ABS

    CIA, EIA (NEW)

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    YEARSWEEKS

    TIME POST-INFECTIONTIME OF

    INFECTION

  • 27

    TREPONEMAL TESTS(TPPA, FTA-ABS)

    WEEKS

    TIME POST-INFECTIONTIME OF

    INFECTION

    YEARS

    NONTREPONEMAL TESTS(RPR, VDRL)

    TREPONEMAL TESTS(TPPA, FTA-ABS)

    WEEKS

    TIME POST-INFECTIONTIME OF

    INFECTION

    YEARS

    UNTREATED

    TREATED

  • 28

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    NONTREPONEMAL TESTS

    RPR, VDRL

    FOLLOWS RESPONSE TO TREATMENT

    1:1 1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024

  • 29

    1:1 1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024

    2-FOLD CHANGE

    1:1 1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024

    2-FOLD CHANGE

    4-FOLD CHANGE [SIGNIFICANT]

  • 30

    NONTREPONEMAL TESTS

    RPR, VDRL

    FOLLOWS RESPONSE TO TREATMENT

    CAN VARY DAILY

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    NONTREPONEMAL TESTS

    RPR, VDRL

    FOLLOWS RESPONSE TO TREATMENT

    CAN VARY DAILY

    ARE FALSE POSITIVES

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 31

    NONTREPONEMAL TESTS

    RPR, VDRL

    FOLLOWS RESPONSE TO TREATMENT

    CAN VARY DAILY

    ARE FALSE POSITIVES

    ARE RARE FALSE NEGATIVES

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    TREPONEMAL TESTS

    TPPA, FTA-ABS, CIA/EIA

    .

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 32

    TREPONEMAL TESTS

    TPPA, FTA-ABS, CIA/EIA

    .GOOD, EARLY PERFORMANCE

    REACTIVITY PERSISTS OVER TIME

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    TREPONEMAL TESTS

    TPPA, FTA-ABS, CIA/EIA

    .GOOD, EARLY PERFORMANCE

    REACTIVITY PERSISTS OVER TIME

    LESS FALSE POSITIVES (FTA, EIA MAIN PROBLEM)

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 33

    NONTREPONEMAL TESTS

    RPR, VDRL

    TREPONEMAL TESTS

    TPPA, FTA-ABS, CIA/EIA

    .

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    NONTREPONEMAL TESTS

    RPR, VDRL

    TREPONEMAL TESTS

    TPPA, FTA-ABS, CIA/EIA

    .

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 34

    Am J OB and GYN, April 2017

    TRADITIONAL

    NONTREPONEMAL (RPR)

    Am J OB and GYN, April 2017

    TRADITIONAL

    NONTREPONEMAL (RPR)

  • 35

    Am J OB and GYN, April 2017

    TRADITIONAL

    NONTREPONEMAL (RPR)

    TREPONEMAL

    Am J OB and GYN, April 2017

    TRADITIONAL

    NONTREPONEMAL (RPR)

    TREPONEMAL

  • 36

    Am J OB and GYN, April 2017

    TRADITIONAL

    NONTREPONEMAL (RPR)

    TREPONEMAL

    TREPONEMAL (EIA/CIA)

    REVERSE

    Am J OB and GYN, April 2017

    TRADITIONAL

    NONTREPONEMAL (RPR)

    TREPONEMAL

    TREPONEMAL (EIA/CIA)

    REVERSE

  • 37

    Am J OB and GYN, April 2017

    TRADITIONAL

    NONTREPONEMAL (RPR)

    TREPONEMAL

    TREPONEMAL (EIA/CIA)

    NONTREPONEMAL (RPR)

    REVERSE

    Am J OB and GYN, April 2017

    TRADITIONAL REVERSE

    NONTREPONEMAL (RPR)

    TREPONEMAL

    TREPONEMAL (EIA/CIA)

    NONTREPONEMAL (RPR)

    TREPONEMAL (TPPA)

  • 38

    Am J OB and GYN, April 2017

    TRADITIONAL REVERSE

    NONTREPONEMAL (RPR)

    TREPONEMAL

    TREPONEMAL (EIA/CIA)

    NONTREPONEMAL (RPR)

    TREPONEMAL (TPPA)

    Am J OB and GYN, April 2017

    TRADITIONAL REVERSE

    NONTREPONEMAL (RPR)

    TREPONEMAL

    TREPONEMAL (EIA/CIA)

    NONTREPONEMAL (RPR)

    TREPONEMAL (TPPA)

  • 39

    Am J OB and GYN, April 2017

    TRADITIONAL REVERSE

    NONTREPONEMAL (RPR)

    TREPONEMAL

    TREPONEMAL (EIA/CIA)

    NONTREPONEMAL (RPR)

    TREPONEMAL (TPPA)

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    STAGING

  • 40

    SYMPTOMS = PRIMARY / SECONDARY STAGES

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    NO SYMPTOMS = LATENT STAGES

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 41

    NO SYMPTOMS = LATENT STAGES

    EARLY IF IN PAST YEAR

    NEG SYPHILIS SEROLOGY

    KNOWN CONTACT TO EARLY CASE OF SYPHILIS

    HISTORY OF SYMPTOMS

    SUSTAINED 4x INCREASE

    ONLY POSSIBLE EXPOSURE

    LATE IF IN PAST YEAR

    (NONE OF THOSE)

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 42

    SYMPTOM RECOGNITION

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 43

    SYMPTOM RECOGNITION

    EMPIRICALLY TREAT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    SYMPTOM RECOGNITION

    PARTNERS WITHIN 90 DAYS

    EMPIRICALLYTREAT

    EMPIRICALLY TREAT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 44

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    GET HISTORYTREATMENT NEEDED?

  • 45

    SYMPTOM RECOGNITION

    PARTNERS WITHIN 90 DAYS

    EMPIRICALLYTREAT

    EMPIRICALLY TREAT

    PRIMARY SECONDARY

    GET HISTORY

    TERTIARYEARLYLATENTLATE

    LATENT

    TREATMENT NEEDED?

    BENZATHINE PENICILLIN G 2.4 MILLION UNITS IM

    x 1, ONCE

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 46

    BENZATHINE PENICILLIN G 2.4 MILLION UNITS IM

    x 1, ONCE

    BENZATHINE PENICILLIN G 2.4 MILLION UNITS IM

    x 3, Q WEEK

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    DAY OF TREATMENT CHECKLIST

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 47

    GET A TITER (REALLY).

    DAY OF TREATMENT CHECKLIST

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    GET A TITER (REALLY).

    DAY OF TREATMENT CHECKLIST

    DAY OF INITIAL LAB TEST DAY OF TREATMENT DAY OF FOLLOW UP

    RPR 1:256 RPR 1:256RPR 1:1024

    [NOT CHECKED]

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 48

    GET A TITER (REALLY).

    WARN ABOUT JARISCH-HERXHEIMER.

    DAY OF TREATMENT CHECKLIST

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    GET A TITER (REALLY).

    WARN ABOUT JARISCH-HERXHEIMER.

    COUNSEL NO SEX x 1 WEEK.

    DAY OF TREATMENT CHECKLIST

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 49

    GET A TITER (REALLY).

    WARN ABOUT JARISCH-HERXHEIMER.

    COUNSEL NO SEX x 1 WEEK.

    ADVISE THAT ALL PARTNERS BE EVALUATED.

    DAY OF TREATMENT CHECKLIST

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    GET A TITER (REALLY).

    WARN ABOUT JARISCH-HERXHEIMER.

    COUNSEL NO SEX x 1 WEEK.

    ADVISE THAT ALL PARTNERS BE EVALUATED.

    CONFIRM HAS BEEN TESTED FOR HIV.

    DAY OF TREATMENT CHECKLIST

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 50

    GET A TITER (REALLY).

    WARN ABOUT JARISCH-HERXHEIMER.

    COUNSEL NO SEX x 1 WEEK.

    ADVISE THAT ALL PARTNERS BE EVALUATED.

    CONFIRM HAS BEEN TESTED FOR HIV.

    ESTABLISH FOLLOW-UP EXPECTATIONS.

    DAY OF TREATMENT CHECKLIST

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    FOLLOW UP

  • 51

    FOLLOW UP

    SEROLOGIC TESTS ~Q6 MONTHS.

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    HIV (-) HIV (+)

    PRIMARY / SECONDARY SYPHILIS

    6, 12 MONTHS

    3, 6, 9, 12, 24 MONTHS

    EARLY LATENT / LATE LATENT SYPHILIS

    6, 12, 24MONTHS

    6, 12, 18, 24MONTHS

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    FOLLOW UP

    SEROLOGIC TESTS ~Q6 MONTHS.

    TREATMENT RESPONSE: 4X TITER DECLINE BY 12 (P/S) OR 24 MO.

  • 52

    SEROLOGIC TESTS ~Q6 MONTHS.

    TREATMENT RESPONSE: 4X TITER DECLINE BY 12 (P/S) OR 24 MO.

    SUSPECTED TREATMENT FAILURE OR REINFECTION IF:

    4-FOLD INCREASE IN TITERS

    OR NEWLY SYMPTOMATIC

    OR TITERS DON’T DECLINE

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    FOLLOW UP

    SEROLOGIC TESTS ~Q6 MONTHS.

    TREATMENT RESPONSE: 4X TITER DECLINE BY 12 (P/S) OR 24 MO.

    SUSPECTED TREATMENT FAILURE OR REINFECTION IF:

    4-FOLD INCREASE IN TITERS

    OR NEWLY SYMPTOMATIC

    OR TITERS DON’T DECLINE

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    FOLLOW UP

    NEW HIV TEST? LP for CSF VDRL

    ? RETREAT (BICILLIN x3)

  • 53

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 54

    DATA

    DATA PARTNERS

  • 55

    DATA PARTNERS POLICY

    DATA PARTNERS POLICY ANSWERS

  • 56

    DATA PARTNERS POLICY ANSWERS

    DATA PARTNERS POLICY ANSWERS

    CALL PUBLIC HEALTH

  • 57

    .

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

    .

    PRIMARY SECONDARY TERTIARYEARLYLATENTLATE

    LATENT

  • 58

    [email protected]

    Joseph EngelmanKristen Herrick

    Susan RobinsonStephanie Cohen

    Laura DaltonPaul Bloomquist

    CAPTCRoxanne Ereth

    Rebecca ScrantonTymeckia KendallDon Herrington

    ACKNOWLEDGEMENTS

  • 59

    EXTRA SLIDES

  • 60

    Rac Syphilis in Pregnancy OB GYN

  • 61

  • 62

    STAGE STARTS LASTS (untreated) Other sxs Infectivity

    Primary 10d‐12 weeks after inoculation (median time 21 d)

    1‐6 weeks • Papule‐>Chancre• Nontender regional adenopathy

    • Infectious by direct contact or blood

    Secondary • 2‐8 weeks after chancre heals or

    • 4‐8 weeks after onset of chancre

    • can overlap with 1ary

    “Several weeks” • symmetric, bilateral rash• mucous patches/condyloma lata• fever, headache, pharyngitis• hepatitis, osteitis, 

    glomerulonephritis• meningitis/ocular/oto‐

    • Infectious by direct contact (when mucosal lesions present) or blood 

    Early Latent After resolution of 2ary symptoms

    • Until 1 year after inoculation

    • can alternate with2ary

    • Neurologic: meningitis, ocular, oto‐, meningovascular (strokes)

    • Infectious by direct contact (when mucosal lesions present) or blood

    Late Latent 1 year after inoculation Until treatment or development of late symptomatic disease

    • Infectious by blood

    Late Symptomatic

    15‐25 years after inoculation

    Until treatment  • General paresis (CNS parenchyma)

    • Tabes dorsalis (posterior columns: sensory/proprio)

    • Cardiac (aortitis, infarction)• Late benign (gummatous)

    Ghanem. CNS Neuroscience & Therapeutics 2010;6(5): e157-68

  • 63

    “Know syphilis in all its manifestations and relations, and all other things clinical will be added unto you.” – William Osler, 1909

    “Syphilis… remains the despair of the statistician.” -- William Osler, 1917

    “When it comes to syphilis, suspect your grandmother” – William Osler

    “The souls of infants born only to die or suffer, cry out against the infamy of uncured syphilis.” – (well known venereal syphilologist)

    “With our present appropriations, Federal and State and private, we might just as well try to empty the Pacific Ocean with a teaspoon.” – Dr. OC Wenger, 1926